- Ongoing, recruitingTherapeutic use (Phase IV)
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS
This study looks at how long people with a certain type of pancreatic cancer live after receiving treatment. It specifically focuses on real-world experiences with common chemotherapy drugs before surgery.
For: Resectable pancreatic adenocarcinoma with risk factorsSpain - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
J1S-MC-JP04: A Randomized, Open-Label Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s Sarcoma
This study is looking at a new way to treat Ewing's sarcoma that has come back or hasn’t responded to previous treatments. It uses a tablet called Verzenios (abemaciclib) along with two chemotherapy drugs, irinotecan and temozolomide. Researchers want to see how well this combination stops the cancer from growing.
For: Ewings SarcomaItaly · Spain · France - Active not recruitingPHASE1
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
This study is testing a new drug, HRO761, for cancers that have specific DNA changes called MSI-high or dMMR. It aims to find a safe and effective dose of HRO761, alone or with other cancer medicines, and see how well it treats these cancers.
For: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersUnited States · Belgium · China - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
This study is testing a new drug called PM14 alongside an existing cancer medicine, Irinotecan, for people with advanced solid cancers. It aims to find the safest and most effective dose of PM14 and see how well the combination shrinks tumours and how the body handles the new medicine.
For: Patients with Selected Advanced Solid TumorsSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial)
This study looks at new ways to treat small cell lung cancer that has come back. It compares a drug called lurbinectedin, alone or with irinotecan, against standard treatments to see which helps patients live longer and clearer of cancer.
For: Small Cell Lung Cancer (SCLC)Poland · France · Germany - Active not recruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study compares a new treatment called Sacituzumab Tirumotecan with standard care for recurrent or metastatic cervical cancer. It aims to see if the new treatment improves how long people live when current treatments aren't enough.
For: Cervical CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Brazil · Canada - RecruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
For: Advanced Cancer · Metastatic Cancer · Ovarian CancerUnited States · France · Spain - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - RecruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
For: Ewing Sarcoma · Colorectal AdenocarcinomaUnited States · France · Italy - Active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
For: Ewing Sarcoma · Solid Tumors · Rhabdoid TumorUnited States · Brazil · Canada - RecruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
For: Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract CancerUnited States · Australia · Canada - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer
This study is testing a new medicine, ompenaclid, for people with advanced bowel cancer that has a specific genetic change called a RAS mutation. It compares ompenaclid with a dummy pill when added to standard chemotherapy and another drug to see if it helps shrink tumours.
For: such as those associated with RAS mutations.Spain · Belgium · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
This study is testing a new drug (Tisotumab Vedotin) for cervical cancer that has come back or spread, and hasn't responded to previous treatments. It compares whether the new drug works better than standard chemotherapy to help people live longer.
For: Second- or Third-Line Recurrent or Metastatic Cervical CancerSweden · Czechia · Finland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
I3Y-MC-JPCS: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).
This study is testing a new medicine, abemaciclib, combined with other treatments for children and young adults with solid cancers that have come back or not responded to previous treatment. Researchers want to find the safest and most effective dose.
For: Relapsed/Refractory Solid TumorsSpain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
This study is testing a new combination of medicines, lurbinectedin and irinotecan, for people with advanced cancers that have already been treated. It aims to find the right dose and see how well it works and if it's safe.
For: Selected Advanced Solid TumorsSpain · France · Italy - Ongoing, recruitingPhase II and Phase III (Integrated)
Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial.
This study is looking at a new way to treat advanced stomach cancer that has a high chance of coming back in the tummy area. It tests a chemotherapy drug called Irinotecan, given into the tummy during surgery, to see if it can help prevent the cancer from returning and improve quality of life.
For: Gastric CarcinomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 54 SAMCO : MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
This study compares a new drug, avelumab, with standard chemotherapy for advanced bowel cancer that has spread and has specific genetic changes (microsatellite instability). We want to see if avelumab can stop the cancer from growing for longer.
For: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITYFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter, open-label, randomized, 2-arm, phase II study to evaluate the efficacy and safety of cetuximab plus irinotecan rechallenge compared with investigator's choice of therapy in the third-line setting in ctDNA genomically selected patients with metastatic colorectal cancer (CITRIC Study)
This study looks at a new treatment for advanced bowel cancer that has spread. It compares two approaches: a drug combination called cetuximab and irinotecan, versus standard care. Doctors want to see which is more effective and safer for patients whose cancer has specific genetic markers.
For: metastatic colorectal cancerSpain - AuthorisedTherapeutic confirmatory (Phase III)
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
This study is looking at different chemotherapy treatments for people in the UK who have had pancreatic cancer removed by surgery. It aims to find out which treatment works best to stop the cancer from coming back by comparing standard care with a new way of choosing treatment based on genetic information.
For: Resected pancreatic ductal adenocarcinomaGermany · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma
This study looks at new ways to treat children with neuroblastoma that has come back or not responded to previous treatments. It combines standard chemotherapy drugs with a new medicine called bevacizumab to see if this helps shrink the cancer or stop it from growing.
For: NeuroblastomaBelgium · Spain · Netherlands - Active not recruitingPHASE3
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study looks at a new medicine, sacituzumab tirumotecan, for advanced stomach or oesophagus cancer. It compares this new medicine to standard treatments to see if it's safer and works better for patients who have already had other treatments.
For: Gastroesophageal CancerUnited States · Belgium · Brazil - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
This study is for people with advanced bowel cancer where previous chemotherapy hasn't worked. It compares a new drug called amivantamab, plus standard FOLFIRI chemotherapy, against other established treatments (cetuximab or bevacizumab) with FOLFIRI, to see which works best.
For: Colorectal NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium - AuthorisedTherapeutic exploratory (Phase II)
Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)
This study looks at different ways to give a common chemotherapy treatment (FOLFIRI) for advanced bowel cancer. Researchers want to see if giving it less often works just as well at keeping the cancer under control, while hopefully making treatment easier for patients.
For: Metastatic colorectal cancerHungary - AuthorisedPhase I and Phase II (Integrated)- Other
BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma
This study, BEACON 2, is looking for better ways to treat neuroblastoma, a type of cancer, in young people and adults when it has come back or not responded to previous treatments. It tests new combinations of existing medicines.
For: High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma) · which is histologically proven as per International Neuroblastoma Staging System (INSS) definition.France · Austria · Germany - AuthorisedTherapeutic use (Phase IV)
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial
This study looks at new ways to treat advanced bowel cancer that has specific genetic features. Researchers want to see if combining existing treatments can shrink tumours early and help people live longer, while also improving their quality of life.
For: advanced colorectal cancer with wild-type RAS and right primary tumour location (right-PTL)Italy · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
This study looks at new treatments for advanced stomach or gastro-oesophageal junction cancer that has grown despite earlier chemotherapy. We're testing if adding two new drugs, domvanalimab and zimberelimab, to standard chemotherapy (FOLFIRI) helps patients live longer without their cancer getting worse.
For: stomach cancer · Esophage · gastro-oesophageal junction adenocarcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11
This study looks at different ways to give cetuximab with other drugs (FOLFIRI) for advanced bowel cancer that has spread. It wants to see if giving cetuximab continuously or in breaks affects how well the treatment works and patients' quality of life.
For: metastatic colorectal cancerGermany